Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesNovartis AG

Novartis AG

PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:28:52.048639Z
Market Cap
195431.30M

Momentum Score

…

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
87.17
Low
131.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
128.38
Dividend Yield
-
Revenue TTM
56674.00M
Revenue Per Share
29.23
Gross Profit TTM
43054.00M
Debt / Equity
0.36
ROE
30.81%
Net Debt
-
ROCE
12.66%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - 26137.00M 9878.00M 8940.00M 14095.00M
Net income - 24021.00M 8072.00M 11732.00M 12611.00M
Selling general administrative - 14815.00M 14093.00M 14319.00M 13690.00M
Gross profit - 37442.00M 35498.00M 34694.00M 32462.00M
Ebit 12859.00M 12824.00M 10152.00M 9086.00M 8924.00M
Operating income - 11689.00M 10152.00M 9086.00M 14193.00M
Other operating expenses 449.00M 653.00M 1448.00M 1395.00M 459.00M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision - 2119.00M 1807.00M 1793.00M 1295.00M
Interest income - 14628.00M 146.00M 36.00M 5.00M
Extraordinary items - - - 4590.00M -186.00M
Income tax expense 1416.00M 2119.00M 1807.00M 1793.00M 1295.00M
Total revenue - 52877.00M 49898.00M 48624.00M 46017.00M
Cost of revenue - 15435.00M 14400.00M 13930.00M 13555.00M
Discontinued operations - - - 4590.00M -186.00M
Net income applicable to common shares 6955.00M 24021.00M 8072.00M 11732.00M 12611.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - 131795.00M 127778.00M 118370.00M 145563.00M
Intangible assets - 34182.00M 36809.00M 28787.00M 38719.00M
Other current assets 297.00M 163.00M 232.00M 1051.00M 1036.00M
Total liab - 64140.00M 71180.00M 62896.00M 66949.00M
Total stockholder equity - 67655.00M 56598.00M 55474.00M 78614.00M
Deferred long term liab 4421.00M 5499.00M 4700.00M 5424.00M 15047.00M
Other current liab 11941.00M 12936.00M 12082.00M 10383.00M 9210.00M
Common stock 890.00M 901.00M 913.00M 936.00M 944.00M
Retained earnings 63540.00M 70989.00M 57157.00M 59275.00M 82191.00M
Other liab 7592.00M 9242.00M 10075.00M 12499.00M 14794.00M
Good will - 29595.00M 29999.00M 26524.00M 35294.00M
Other assets 10218.00M 12425.00M 10447.00M 14799.00M 25549.00M
Cash - 9011.00M 5908.00M 7865.00M 10150.00M
Total current liabilities 28656.00M 30208.00M 33059.00M 28264.00M 29607.00M
Short term debt - 3606.00M 7319.00M 4844.00M 6430.00M
Short long term debt total - 24523.00M 27978.00M 22056.00M 22470.00M
Other stockholder equity -4996.00M -4187.00M -1419.00M -4657.00M -4452.00M
Property plant equipment 12195.00M 13106.00M 13939.00M 13746.00M 15696.00M
Total current assets 36910.00M 45718.00M 29673.00M 29504.00M 35563.00M
Net tangible assets 2818.00M 9377.00M -5510.00M 5587.00M 19648.00M
Short term investments - 15706.00M 1635.00M 122.00M 2447.00M
Net receivables 9801.00M 9563.00M 9963.00M 10229.00M 10925.00M
Long term debt - 22902.00M 26259.00M 20353.00M 22470.00M
Inventory 7175.00M 6666.00M 7131.00M 5982.00M 6956.00M
Accounts payable 5146.00M 5553.00M 5403.00M 5424.00M 5556.00M
Treasury stock - -48.00M -53.00M -80.00M -69.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 4650.00M 6815.00M -922.00M
Change to liabilities - - -48.00M -21.00M -324.00M
Total cashflows from investing activities - - 1468.00M 4208.00M -13182.00M
Net borrowings - - -2559.00M -5986.00M 7072.00M
Total cash from financing activities - - -20562.00M -16264.00M -2208.00M
Change to operating activities - - -421.00M -549.00M -1998.00M
Net income 11939.00M 14854.00M 6955.00M 24021.00M 8072.00M
Change in cash - - -4890.00M 2749.00M -1454.00M
Total cash from operating activities - - 14236.00M 15071.00M 13650.00M
Depreciation - - 5448.00M 5429.00M 5110.00M
Other cashflows from investing activities - - -1.00M -57.00M -186.00M
Dividends paid - - 7506.00M 7368.00M 6987.00M
Change to inventory - - -830.00M 81.00M -543.00M
Change to account receivables - - -589.00M -389.00M 137.00M
Sale purchase of stock - - - -3004.00M -2094.00M
Other cashflows from financing activities - - 55.00M 94.00M -199.00M
Change to netincome - - 3721.00M -13501.00M 3196.00M
Capital expenditures 0.00M 0.00M 1198.00M 1378.00M 1275.00M
Change in working capital - - - -3346.00M -4727.00M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Lichtstrasse 35, Basel, Switzerland, 4056

41 61 324 11 11

https://www.novartis.com

75267

Name Title Year Born
Dr. Vasant Narasimhan Chief Exec. Officer 1976
Mr. Harry Kirsch Chief Financial Officer 1965
Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer 1968
Ms. Karen L. Hale Chief Legal Officer 1968
Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer 1968
Mr. Steffen Lang Ph.D. Pres of Operations 1967
Ms. Marie-France Tschudin Pres of Innovative Medicines International & Chief Commercial Officer 1971
Mr. Richard Saynor Chief Exec. Officer of Sandoz 1967
Paul Penepent Head of Group Financial Reporting and Accounting NA
Dr. Samir Shah M.D. Global Head of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…